|
|
|
Volumn 6, Issue 3, 2004, Pages 331-336
|
|
Technology evaluation: ISIS-113715, Isis
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
ANTIDIABETIC AGENT;
ANTISENSE OLIGONUCLEOTIDE;
DRUG METABOLITE;
DRUG VEHICLE;
HYDROLASE INHIBITOR;
INSULIN;
INSULIN SENSITIZING AGENT;
ISIS 107772;
ISIS 113715;
PHOSPHOPROTEIN PHOSPHATASE INHIBITOR;
PLACEBO;
PROTEIN TYROSINE PHOSPHATASE 1B;
PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG DISPOSITION;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG IDENTIFICATION;
DRUG INDICATION;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG RESEARCH;
DRUG SYNTHESIS;
DRUG TISSUE LEVEL;
DRUG TOLERABILITY;
ENZYME INHIBITION;
GENE MUTATION;
HUMAN;
HYPOGLYCEMIA;
INSULIN BLOOD LEVEL;
INSULIN RESISTANCE;
INSULIN SENSITIVITY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
NUCLEOTIDE SEQUENCE;
OBESITY;
SHORT SURVEY;
SIDE EFFECT;
STRUCTURE ACTIVITY RELATION;
TOXICITY TESTING;
ANIMALS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DIABETES MELLITUS, TYPE 2;
FEMALE;
HUMANS;
MALE;
MICE;
MICE, KNOCKOUT;
OLIGORIBONUCLEOTIDES;
OLIGORIBONUCLEOTIDES, ANTISENSE;
PATENTS;
PROTEIN-TYROSINE-PHOSPHATASE;
|
|
EID: 3242883637
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (53)
|
|
References (0)
|
